Oncotarget

Research Papers:

Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit

Wuguang Lu, Lingchong Qiu, Zhanpeng Yan, Zhibing Lin, Meng Cao, Chunping Hu, Zhigang Wang, Jin Wang, Ye Yu, Xiaoyang Cheng, Peng Cao, Rongxiu Li _

PDF |  HTML  |  Supplementary Files  |  Author Information  |  Order a Reprint

Oncotarget. 2015; 6:34537-34548. https://doi.org/10.18632/oncotarget.5307

Metrics: HTML 285 views  |   ?  


Abstract

Wuguang Lu1,2,5, Lingchong Qiu1, Zhanpeng Yan2,5, Zhibing Lin1, Meng Cao2,5, Chunping Hu2,5, Zhigang Wang2,5, Jin Wang3, Ye Yu3, Xiaoyang Cheng3, Peng Cao2,5, Rongxiu Li1,4

1State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China

2Laboratory of Cellular and Molecular Biology, Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China

3Institute of Medical Science and Department of Pharmacology and Physiology, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China

4Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China

5Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China

Correspondence to:

Rongxiu Li, e-mail: rxli@sjtu.edu.cn

Peng Cao, e-mail: pcao79@yahoo.com

Keywords: immunotherapy, MUC1, antigen design, cytotoxic T cell response, vaccine

Received: March 22, 2015     Accepted: September 08, 2015     Published: September 21, 2015

ABSTRACT

Induction of cytotoxic T lymphocytes (CTL) is critical to cancer vaccine based immunotherapy. Efforts to elicit CTLs against tumor MUC1 with peptide based vaccine have not been successful in clinical application. We have design a MUC1 vaccine by replacing B cell epitope of CTB with MUC1 VNTR peptide. Immunization with hybrid CTB-MUC1 plus aluminum hydroxide and CpG adujuvant (CTB-MUC1-Alum-CpG) induce MUC1-specific CTLs in mice. Moreover, this vaccination can prevent tumor growth and reduce tumor burden in MUC1+B16 mice model. Meanwhile, CTB-MUC1-Alum-CpG vaccination can promote Th1 cells and CD8+ T cells inflate to tumor tissue. Our approach might be applicable to other cancer vaccine design.

Author Information

Wuguang Lu

Lingchong Qiu

Zhanpeng Yan

Zhibing Lin

Meng Cao

Chunping Hu

Zhigang Wang

Jin Wang

Ye Yu

Xiaoyang Cheng

Peng Cao

Rongxiu Li
Primary Contact  _


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5307